Clinical characteristics and prognosis of interstitial lung disease in systemic juvenile idiopathic arthritis: a two-center retrospective observational cohort study
- PMID: 39449050
- PMCID: PMC11515563
- DOI: 10.1186/s12969-024-01028-5
Clinical characteristics and prognosis of interstitial lung disease in systemic juvenile idiopathic arthritis: a two-center retrospective observational cohort study
Abstract
Background: Interstitial lung disease (ILD) is a serious complication in systemic juvenile idiopathic arthritis (SJIA). This study aimed to identify the clinical characteristics and prognosis of SJIA-ILD.
Methods: A two-center retrospective cohort study was conducted on patients newly diagnosed with SJIA in China from October 2010 to December 2021. Clinical characteristics, laboratory parameters, outcomes, and relapse rates were compared between ILD and non-ILD groups.
Results: A total of 176 children with SJIA were included, including 35 in ILD group and 141 in non-ILD group. The median age at onset of SJIA was 5.8 years (range 4.4-9.5) in patients with SJIA-ILD. It exhibited higher incidences of cervical spine (28.6%) and hip involvement (40.0%) in ILD group (P = 0.031 and P = 0.029, respectively). The incidence of macrophage activation syndrome (MAS) in ILD group reached up to 40%, significantly elevated than that in non-ILD group (P = 0.047). Children with ILD demonstrated a stronger inflammatory response and were more prone to developing lymphopenia (P = 0.009), requiring more combination therapy (P = 0.006) to control disease activity. 54.3% of patients received biologic therapies, with only three patient receiving biologics (one with IL-6 blockade, two with TNF inhibitor) prior to ILD onset and none receiving IL-1 blockade. The median follow-up duration was 6.0 years (range 3.9-9.5). The proportions of patients with SJIA-ILD achieving clinical inactive disease without glucocorticoids within 6 to 12 months of the treatment were significantly lower than control group (45.7% vs. 70.2%, P = 0.006). In ILD group, only 54.3% of patients achieved complete remission, and 17.1% were in a non-remission state, among whom two deaths from respiratory failure. There was no significant difference in disease relapse rates between the two groups (P > 0.05).
Conclusions: Patients with SJIA-ILD exhibited heightened inflammation, increased hip joint and cervical spine involvement, and were more susceptible to developing lymphopenia and MAS, suggesting a relatively poor prognosis. They required a prolonged time to control inflammation and more aggressive treatment strategies to achieve inactive status. The unsatisfactory rate of complete remission highlighted an urgent need for focused clinical strategies.
Keywords: Interstitial lung disease; Juvenile idiopathic arthritis; Pediatrics; Rheumatology.
© 2024. The Author(s).
Conflict of interest statement
No competing interests.
Figures
Similar articles
-
Clinical manifestations, treatment and prognosis of juvenile idiopathic arthritis with pulmonary involvement in China: a single centre study.Clin Exp Rheumatol. 2024 Nov;42(11):2303-2311. doi: 10.55563/clinexprheumatol/udjbtq. Epub 2024 Sep 9. Clin Exp Rheumatol. 2024. PMID: 39263798
-
Characterization of Patients with Macrophage Activation Syndrome Secondary to Systemic Juvenile Idiopathic Arthritis.Clin Rheumatol. 2025 May;44(5):2023-2029. doi: 10.1007/s10067-025-07420-0. Epub 2025 Mar 27. Clin Rheumatol. 2025. PMID: 40146446
-
Systemic juvenile idiopathic arthritis-associated lung disease: A retrospective cohort study.World J Clin Pediatr. 2024 Mar 9;13(1):88912. doi: 10.5409/wjcp.v13.i1.88912. eCollection 2024 Mar 9. World J Clin Pediatr. 2024. PMID: 38596441 Free PMC article.
-
Refractory systemic onset juvenile idiopathic arthritis: current challenges and future perspectives.Ann Med. 2022 Dec;54(1):1839-1850. doi: 10.1080/07853890.2022.2095431. Ann Med. 2022. PMID: 35786149 Free PMC article. Review.
-
Treatment of systemic juvenile idiopathic arthritis.Nat Rev Rheumatol. 2023 Dec;19(12):778-789. doi: 10.1038/s41584-023-01042-z. Epub 2023 Nov 3. Nat Rev Rheumatol. 2023. PMID: 37923864 Review.
Cited by
-
Advancing multidisciplinary management of pediatric hyperinflammatory disorders.Front Pediatr. 2025 Apr 30;13:1553861. doi: 10.3389/fped.2025.1553861. eCollection 2025. Front Pediatr. 2025. PMID: 40370972 Free PMC article. Review.
-
Utility of patient-reported outcomes for pulmonary symptoms and sleep disturbance and impairment in children with systemic juvenile idiopathic arthritis.Pediatr Rheumatol Online J. 2025 Jul 15;23(1):74. doi: 10.1186/s12969-025-01126-y. Pediatr Rheumatol Online J. 2025. PMID: 40665383 Free PMC article.
References
-
- Kumar S. Systemic juvenile idiopathic arthritis: diagnosis and management. Indian J Pediatr. 2016;83(4):322–7. - PubMed
-
- Martini A. Systemic juvenile idiopathic arthritis. Autoimmun Rev. 2012;12(1):56–9. - PubMed
-
- Minoia F, Davì S, Horne A, Demirkaya E, Bovis F, Li C, et al. Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, Multicenter Study of 362 patients. Arthritis Rheumatol. 2014;66(11):3160–9. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical